Anzeige
Mehr »
Login
Montag, 27.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Hinter dem nuklearen Ansturm im Silicon Valley: Eine strategische Chance entsteht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CM1B | ISIN: US00974H1041 | Ticker-Symbol:
NASDAQ
27.01.25
19:35 Uhr
3,000 US-Dollar
-0,070
-2,28 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
AKOYA BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
AKOYA BIOSCIENCES INC 5-Tage-Chart

Aktuelle News zur AKOYA BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.01.Quanterix To Buy Akoya Biosciences For Creating An Integrated Solution For Detection Of Protein Biomarkers3
10.01.Akoya Biosciences, Inc. - 8-K, Current Report-
10.01.Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers148BILLERICA, Mass. and MARLBOROUGH, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences...
► Artikel lesen
13.12.24Akoya Biosciences, Inc. - 8-K, Current Report-
10.12.24Akoya Biosciences and NeraCare enter into a license agreement6
AKOYA BIOSCIENCES Aktie jetzt für 0€ handeln
10.12.24Akoya Biosciences, Inc.: Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions1
14.11.24Akoya Biosciences, Inc. - 10-Q, Quarterly Report1
28.10.24Akoya Biosciences, Inc.: Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 20242
07.10.24Akoya Biosciences, Inc.: Akoya's Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy1
03.10.24Akoya Biosciences, Inc.: Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors1
03.10.24Akoya Biosciences, Inc. - 8-K, Current Report1
05.08.24Akoya Biosciences GAAP EPS of -$0.27 in-line, revenue of $23.2M misses by $0.35M1
05.08.24Akoya Biosciences, Inc. - 8-K, Current Report1
05.08.24Akoya Biosciences, Inc.: Akoya Biosciences Reports Second Quarter 2024 Financial Results244MARLBOROUGH, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the second quarter ending...
► Artikel lesen
13.05.24Akoya Biosciences, Inc.: Akoya Biosciences Reports First Quarter 2024 Financial Results135MARLBOROUGH, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the first quarter ending...
► Artikel lesen
04.03.24Akoya Biosciences, Inc.: Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook205Q4 2023 revenue $26.5 million and FY 2023 revenue $96.6 millionGuiding FY 2024 revenue range $114.0-118.0 million and operating cash flow breakeven by YE 2024 MARLBOROUGH, Mass., March 04, 2024 (GLOBE...
► Artikel lesen
16 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1